Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation (original) (raw)
Skip to main navigation menu Skip to main content Skip to site footer
Original article
- Frank Stenner
- Stefan Dirnhofer
- Jakob Passweg
- Sabine Gerull
- Jörg P. Halter
- Alfred Zippelius
- Heinz Läubli
Summary
Cancer immunotherapy with immune checkpoint inhibitors (ICIs) such as programmed death ligand-1 (PD-L1) blockers offers pronounced clinical benefit with durable responses and a manageable safety profile. Patients with a high risk of immune-related adverse events are generally excluded from clinical trials testing ICI therapy. Thus, only a little information on the safety and clinical outcome of patients treated with an ICI after allogeneic haematopoietic cell transplantation (HCT) is currently available. Here, we report the characteristics and outcomes of six patients with, respectively, clear cell renal carcinoma, diffuse large cell B-cell lymphoma, Hodgkin lymphoma, a microsatellite instable colorectal cancer and melanoma who were treated with PD-1 blocking antibodies. All patients had previously undergone allogeneic HCT. Severe grade 3–5 immune-related adverse events were observed in three of five patients who received full-dose ICI therapy. One patient received a lower dose of PD-1 blocking antibody. Only one patient had an objective response, whereas all the other patients had progressive disease. The high toxicity of a full- dose anti-PD-1 treatment regimen suggests that other treatment approaches for patients after allogeneic HCT are needed outside of the context of relapsed Hodgkin disease. In cases where ICI therapy is the only treatment option, reduced dosing should be explored.
References
- Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019;2(5):e192535. doi:.https://doi.org/10.1001/jamanetworkopen.2019.2535
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi:.https://doi.org/10.1126/science.aaa8172
- Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61. doi:.https://doi.org/10.1016/j.ccell.2015.03.001
- Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, et al. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol. 2019;37(23):1997–2007. doi:.https://doi.org/10.1200/JCO.19.00315
- Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9. doi:.https://doi.org/10.1056/NEJMoa1411087
- Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O’Donnell E, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611–8. doi:.https://doi.org/10.1158/1078-0432.CCR-11-1942
- Michonneau D, Sagoo P, Breart B, Garcia Z, Celli S, Bousso P. The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. Immunity. 2016;44(1):143–54. doi:.https://doi.org/10.1016/j.immuni.2015.12.008
- Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130(2):221–8. doi:.https://doi.org/10.1182/blood-2017-01-761346
- Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129(18):2471–8. doi:.https://doi.org/10.1182/blood-2016-11-749556
- Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019;25(1):94–9. doi:.https://doi.org/10.1016/j.bbmt.2018.08.028
- Onizuka M, Kojima M, Matsui K, Machida S, Toyosaki M, Aoyama Y, et al. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol. 2017;106(1):141–5. doi:.https://doi.org/10.1007/s12185-017-2181-9
- Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(6):850–2. doi:.https://doi.org/10.1038/bmt.2015.346
- Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–94. doi:.https://doi.org/10.1016/S1470-2045(16)30167-X
- Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. 2016;34(31):3733–9. doi:.https://doi.org/10.1200/JCO.2016.67.3467
- Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–39. doi:.https://doi.org/10.1200/JCO.2017.76.0793
- Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al.; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018;378(4):331–44. doi:.https://doi.org/10.1056/NEJMoa1708984
- Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–8. doi:.https://doi.org/10.1182/blood-2008-07-168468
- Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, et al.; Leukemia and Lymphoma Society Blood Cancer Research Partnership. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143–53. doi:.https://doi.org/10.1056/NEJMoa1601202
- Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(3):1272–7. doi:.https://doi.org/10.4049/jimmunol.171.3.1272
- Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013;122(17):3062–73. doi:.https://doi.org/10.1182/blood-2013-05-500801
- Saha A, O’Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016;126(7):2642–60. doi:.https://doi.org/10.1172/JCI85796
- Juchem KW, Sacirbegovic F, Zhang C, Sharpe AH, Russell K, McNiff JM, et al. PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. J Immunol. 2018;200(2):834–46. doi:.https://doi.org/10.4049/jimmunol.1701076
- Fujiwara H, Maeda Y, Kobayashi K, Nishimori H, Matsuoka K, Fujii N, et al. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. J Immunol. 2014;193(5):2565–73. doi:.https://doi.org/10.4049/jimmunol.1400954
- Danylesko I, Shimoni A. Second Malignancies after Hematopoietic Stem Cell Transplantation. Curr Treat Options Oncol. 2018;19(2):9. doi:.https://doi.org/10.1007/s11864-018-0528-y
- Roziakova L, Bojtarova E, Mistrik M, Mladosievicova B. Secondary malignancies after hematopoietic stem cell transplantation. Neoplasma. 2011;58(1):1–8. doi:.https://doi.org/10.4149/neo_2011_01_1
Most read articles by the same author(s)
- Adalgisa Condoluci, Marie Théaudin, Rahel Schwotzer, Aju P. Pazhenkottil, Paolo Arosio, Manuela Averaimo, Ulrike Bacher, Peter Bode, Andrea Cavalli, Stefan Dirnhofer, Nadia Djerbi, Stephan Dobner, Thomas Fehr, Maura Garofalo, Ariana Gaspert, Sabine Gerull, Raphael Heimgartner, Annemarie Hübers, Hans H. Jung, Chiara Kessler, Raphael Knöpfel, Natallia Laptseva, Giulia Magini, Robert Manka, Luca Mazzucchelli, Martin Meyer, Violeta Mihaylova, Pierre Monney, Alessio Mylonas, René Nkoulou, Thomas Pabst, Otmar Pfister, Axel Rüfer, Adrian Schmidt, Harald Seeger, Simon F. Stämpfli, Guido Stirnimann, Thomas Suter, Giorgio Treglia, Alexandar Tzankov, Friederike Vetter, Markus Zweier, Andreas J. Flammer, Bernhard Gerber, Management of transthyretin amyloidosis, Swiss Medical Weekly: Vol. 151 No. 4142 (2021)
- Rahel Schwotzer, Andreas J. Flammer, Sabine Gerull, Thomas Pabst, Paolo Arosio, Manuela Averaimo, Ulrike Bacher, Peter Bode, Andrea Cavalli, Adalgisa Condoluci, Stefan Dirnhofer, Nadia Djerbi, Stephan W. Dobner, Thomas Fehr, Maura Garofalo, Ariana Gaspert, Raphael Heimgartner, Annemarie Hübers, Hans H. Jung, Chiara Kessler, Raphael Knöpfel, Natallia Laptseva, Robert Manka, Luca Mazzucchelli, Martin Meyer, Violeta Mihaylova, Pierre Monney, Alessio Mylonas, René Nkoulou, Aju P. Pazhenkottil, Otmar Pfister, Axel Rüfer, Adrian Schmidt, Harald Seeger, Simon F. Stämpfli, Guido Stirnimann, Thomas Suter, Marie Théaudin, Giorgio Treglia, Alexandar Tzankov, Friederike Vetter, Markus Zweier, Bernhard Gerber, Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis, Swiss Medical Weekly: Vol. 150 No. 4950 (2020)
- Arnoud J. Templeton, Aurelius Omlin, Dominik Berthold, Jörg Beyer, Irene A. Burger, Daniel Eberli, Daniel Engeler, Christian Fankhauser, Stefanie Fischer, Silke Gillessen, Guillaume Nicolas, Stephanie Kroeze, Anja Lorch, Michael Müntener, Alexandros Papachristofilou, Niklaus Schaefer, Daniel Seiler, Frank Stenner, Petros Tsantoulis, Tatjana Vlajnic, Thomas Zilli , Daniel Zwahlen, Richard Cathomas, Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer, Swiss Medical Weekly: Vol. 153 No. 8 (2023)
- Jakob R. Passweg, Helen Baldomero, Marc Ansari, Gabriela M. Baerlocher, Mario Bargetzi, Yves Chalandon, Michel A. Duchosal, Sabine Gerull, Tayfun Güngör, Jörg P. Halter, Dominik Heim, Urs Hess, Kurt Leibundgut, Stavroula Masouridi-Levrat, Antonia Müller, Gayathri Nair, Thomas Pabst, Christoph Renner, Adrian Schmidt, Georg Stussi, Grazia Nicoloso de Faveri, Urs Schanz, for the Swiss Blood Stem Cell Transplantation Group (SBST), Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997–2016, Swiss Medical Weekly: Vol. 148 No. 0910 (2018)
- Uta Rothschild, Laurent Muller, Axel Lechner, Hans A. Schlöẞer, Dirk Beutner, Heinz Läubli, Alfred Zippelius, Sacha I. Rothschild, Immunotherapy in head and neck cancer – scientific rationale, current treatment options and future directions, Swiss Medical Weekly: Vol. 148 No. 1920 (2018)
- Mario Bargetzi, Reto Baumann, Sergio Cogliatti, Pierre-Yves Dietrich, Michel André Duchosal, Jeroen S. Goede, Felicitas Hitz, Carolin Konermann, Andreas Lohri, Ulrich Mey, Urban Novak, Alexandros Papachristofilou, Frank Stenner, Christian Taverna, Thilo Zander, Christoph Renner, Diagnosis and treatment of follicular lymphoma: an update, Swiss Medical Weekly: Vol. 148 No. 2930 (2018)
- Jakob Passweg, Helen Baldomero, Mario Bargetzi, Christoph Bucher, Yves Chalandon, Michel A. Duchosal, Alois Gratwohl, Tayfun Güngör, Urs Hess, Kurt Leibundgut, Grazia Nicoloso de Faveri, Hulya Ozsahin, Thomas Pabst, Christoph Renner, Martin Stern, Georg Stussi, Urs Schanz, for the SBST (Swiss Blood Stem Cell Transplantation Group), Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries, Swiss Medical Weekly: Vol. 143 No. 0708 (2013)
- Caroline Arber, Gabriela Baerlocher, Yves Chalandon, Michael Daskalakis, Michel Duchosal, Martin Fehr, Sabine Gerull, Tayfun Güngör, Gayathri Nair, Thomas Pabst, Jakob R. Passweg, Barbara Piccolruaz, Christoph Renner, Axel Ruefer, Dominik Schneidawind, Georg Stüssi, Sacha Zeerleder, Jörg P. Halter, Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data, Swiss Medical Weekly: Vol. 154 No. 10 (2024)
- Jeroen S. Goede , Christa K. Baumann, Richard Cathomas, Nina Khanna, Jean-Francois Lambert, Thomas Lehmann, Ulrich J. M. Mey, Jörg Seebach, Urs C. Steiner, Astrid Tschan-Plessl, Frank Stenner, Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies, Swiss Medical Weekly: Vol. 154 No. 9 (2024)
- Silvia Hofer, Kristina Keller, Lukas Imbach, Ulrich Roelcke, Gregor Hutter, Thomas Hundsberger, Caroline Hertler, Emilie Le Rhun, Flavio Vasella, Dominik Cordier, Marian Neidert, Andreas Hottinger, Denis Migliorini, Tobias Pflugshaupt, Noemi Eggenberger, Brigitta Baumert, Heinz Läubli, Dorothee Gramatzki, Michael Reinert, Gianfranco Pesce, Philippe Schucht, Irene Frank, Dirk Lehnick, Tobias Weiss, Hans-Georg Wirsching, Fabian Wolpert, Patrick Roth, Michael Weller, Fitness-to-drive for glioblastoma patients, Swiss Medical Weekly: Vol. 151 No. 1920 (2021)